Page 145«..10 20..144145146 147..150 160..»

Category Archives: Stem Cell Therapy

Mickey’s Before

Posted: June 4, 2013 at 10:45 am

Mickey #39;s Before After Stemlogix Stem Cell Therapy
Mickey, a 13 year old German Shepherd torn both of his ACLs and suffered from severe arthritis. Mickey has been treated with Stemlogix Stem Cell Therapy Platelet Max Platelet Rich Plasma...

By: Stemlogix, LLC

Read the original:
Mickey's Before

Posted in Stem Cell Therapy | Comments Off

Sarasota's Dr. Guy DaSilva Introduces Cutting-Edge Stem Cell Therapy For Degenerative Diseases

Posted: June 4, 2013 at 3:41 am

Sarasota, Florida (PRWEB) June 03, 2013

Guy DaSilva, MD, ABAARM, will begin conducting clinical trials for many degenerative diseases using adipose-derived stem cell therapy at the DaSilva Institute in Sarasota, Florida. The independent review board of the International Stem Cell Society will oversee the trials.

Following the IRB-approved protocols, Dr. DaSilva will treat patients suffering from chronic obstructive pulmonary disease (COPD), Type 2 Diabetes, osteoarthritis, critical limb ischemia and erectile dysfunction. Furthermore, Alzheimers disease, dementia and Parkinsons disease are pending approval, and approximately five new protocols are added each month.

While stem cell therapy is most often associated with the controversial use of embryonic stem cells, Dr. DaSilva will be exclusively using adult autologous stem cells, harvested from the patients own adipose (fat) tissue or bone marrow if fat is not available. Because patients are receiving their own cells, there is no risk of rejection, and success rates are far greater compared to the more contentious therapies.

Autologous stem cell therapy works by mimicking the bodys natural healing process, but at a more potent, concentrated level. Stem cells, which are unspecialized cells with the potential to develop into any cell, are stored throughout the body. When disease or injury strikes, the body sends these cells to the area in need, and they begin repairing and replacing damaged tissue. Stem cell function decreases with age, along with ones ability to heal. But with autologous stem cell therapy, the body is once again empowered to heal and reverse disease, and with much greater magnitude.

Dr. DaSilva trained under scientist Kristin Comella, Chief Science Officer of Bioheart, CEO of Stemlogix, Chief Scientific Officer of the Ageless Regenerative Institute, and was recently named one of the 50 most influential people on stem cells. Dr. DaSilva will implement Comellas patented extraction process to precisely isolate and remove stem cells from fat tissue, allowing for an exceptionally high yield and viability.

During the in-office procedure, a mini liposuction is performed on the patient to remove 60 milliliters of fat, which produces approximately 8 million stem cells. The stem cells are isolated and injected back into the patients body at the site of injury or disease. Only local anesthesia is needed, and the patient will go home pain-free.

Over the next month, the patients body will repair and regenerate itself naturally. Dr. DaSilva will continue to treat the patient, with therapies that range from high dose IV nutrition and heavy metal chelation to bio-identical hormones. This helps the body maintain a healthy environment to further promote cellular and mitochondrial healing.

According to Dr. DaSilva, autologous stem cell therapy is very promising. He says, This extraordinary therapy is going to change the face of medicine. For example, it has the capability to completely reverse Type 2 Diabetes with a single dose, allowing patients to avoid amputations, premature death, and a life of food monitoring and injections. The results are truly remarkable, and this is only the beginning.

About Guy DaSilva, MD, ABAARM

View original post here:
Sarasota's Dr. Guy DaSilva Introduces Cutting-Edge Stem Cell Therapy For Degenerative Diseases

Posted in Stem Cell Therapy | Comments Off

Cellular Dynamics: California Stem Cell Agency Recipient Plans $57 Million IPO

Posted: June 3, 2013 at 10:49 pm

A Wisconsin firm that is the
beneficiary of more than $16 million from the California stem cell
agency today announced that it intends to go public to raise $57.3
million for its iPS cell ventures.

Jamie Thomson
UCSB photo

The firm is Cellular Dynamics
International, Inc., and was co-founded by internationally known stem
cell scientist Jamie Thomson of the University of Wisconsin, who is
currently the company's chief scientific officer. Thomson is also a professor
at UC Santa Barbara, where he is co-director of the Center for Stem
Cell Biology and Engineering.

In March, the California stem cell
agency awarded a $16 million grant to Cellular Dynamics to derive
three iPS cell lines from 3,000 individuals as part of the agency's
stem cell banking initiative. (Here is a link to the grant review summary.)

The company said in its SEC
filings that it also will be the prime subcontractor on a $10 million
grant that the Coriell Institute for Medical Research of Camden,
N.J., received in the agency's stem cell banking round. Cellular Dynamics said
some of the funds from the IPO will be used to complete its
California laboratory in leased space at the Buck Institute in
Novato, north of San Francisco.

Cellular Dynamics was founded in 2004
and sold its first commercial product in 2010. It reported revenues
of $6.6 million in 2012 and losses of $22.3 million. It has 115
full-time and part-time employees worldwide.

The company said,

“During 2011 and 2012, we had three
large biopharmaceutical customers that individually accounted for
greater than 10% of our total revenue in one or both years. Eli Lilly
and Company (Lilly) accounted for 10% of total revenue in 2011 and
18% of total revenue in 2012. Hoffmann-La Roche Inc. (Roche)
accounted for 13% of total revenue in 2011 and GlaxoSmithKline plc
(GSK) accounted for 11% of our total revenue in 2012.”

Cellular Dynamics also said in its
filings,

“Our total revenue grew from $2.6
million in 2011 to $6.6 million in 2012, an increase of 154%. This
growth was driven by a 247% increase in sales of our iCell products
which grew from $1.5 million in 2011 to $5.2 million in 2012. At
December 31, 2011, our backlog of revenue expected to be recognized
in 2012 was $1.1 million. At December 31, 2012, our backlog of
revenue expected to be recognized in 2013 had grown to $4.1 million.

“For the three months ended March 31,
2013 our total revenue was $2.4 million, an increase of 109% over the
corresponding period in 2012. This growth was driven primarily by an
increase in iCell product sales, which grew from $0.6 million for the
three months ended March 31, 2012 to $1.8 million for the three
months ended March 31, 2013, an increase of 173%.”

Paul Knoepfler of UC Davis, writing on his blog, touched on some of the aspects of the IP issues involving
Cellular Dynamics and Japanese researcher Shinya Yamanaka, who won the Nobel Prize last year for discovering how to reprogram adult stem cells into pluripotent cells (the iPS process).

Knoepfler wrote,

"A
recent question is the issue of who has the intellectual property
(IP) rights to iPS cell technology. People have told me in the
past that they wondered if Cellular Dynamics has unambiguous rights
to develop all of these iPS cell-based products."

Knoepfler also wrote,

“This (the IPO) looks to
be very interesting and could transform the field as it develops.”

News coverage today of the IPO filing
was light, but is more expected to surface tomorrow. Here is a link to the only story that had surfaced as of this writing.

No price or date has yet been set for
the offering.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0oup8hU2FGE/cellular-dynamics-california-stem-cell.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Pomeroy on Doing the Right Thing and Foster Care

Posted: June 3, 2013 at 11:38 am

Claire Pomeroy
CIRM photo

On Claire Pomeroy's last day as a
member of the governing board of the $3 billion California stem cell
agency, she also published an essay on the Huffington Post in which
she discussed fleeing from an abusive home at age 14.

Pomeroy, former vice chancellor and
dean of the medical school at UC Davis and now president of the Lasker Foundation in New York, wrote last month,

“For some children, the uncertainty
of life on the street is better than certainty of violence at home.
It was for me. At age 14, I escaped from an abusive home with no
money, nowhere to go and only the clothes I was wearing. I remember
staring into the night, standing somewhere between fear and freedom.
I became one of the millions of homeless teens, yet I was lucky
because foster care ultimately saved me.”
“However, after an emergency
placement and three foster homes, the challenges were not over. At 17
I aged out of the foster care system early when my foster parents
moved out of state. On my own again, I had to find a job, a place to
live and finish high school. Then I climbed the next mountain to
graduate from college and medical school.”

Pomeroy said she only recently began
publicly talking about her foster care experience. She said she is
doing so because “many people lack an understanding of
the harsh statistics and their impact on the country's future. The
nation faces a crisis that demands a call to action to start truly
caring about foster youth before it is too late.”

She said that she was “lucky” in the
foster care system but said that many children, particularly minorities among others such as the disabled, were not as fortunate and “were failed by the system and society.” Pomeroy called them
“throwaway children” who were “robbed of their ideals, gave up
hope and struggled to find a reason to live.”

Less than half of the foster children
who “age out” of the system graduate from high school, she wrote. Only 3
percent to 11 percent earn a bachelor's degree. More than
400,000 children were in foster care in 2011 and have a one in 11 chance
of being homeless.

Pomeroy called for expansion and
improvement of foster care across the country. “It is time to stop
forcing children to be the heroes of their own survival,” she
wrote. “Now is the time to do the right the right thing.”

------

On a personal note, we have four
grandchildren, one of whom was adopted out of foster care as a
toddler. The other was adopted at birth. Some of the siblings of
those two African-American children remain in foster care today.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zancriHTUC4/pomeroy-on-doing-right-thing-and-foster.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Stem Cell Therapy in Spinal Cord Injury – Video

Posted: June 3, 2013 at 3:43 am

Stem Cell Therapy in Spinal Cord Injury

By: Knowlege21

Originally posted here:
Stem Cell Therapy in Spinal Cord Injury - Video

Posted in Stem Cell Therapy | Comments Off

Sarasota’s Dr .Guy DaSilva Introduces Cutting-Edge Stem Cell Therapy For Degenerative Diseases

Posted: June 3, 2013 at 3:43 am

Sarasota, Florida (PRWEB) June 03, 2013

Following the FDA-approved protocols, Dr. DaSilva will treat patients suffering from chronic obstructive pulmonary disease (COPD), Type 2 Diabetes, osteoarthritis, critical limb ischemia and erectile dysfunction. Furthermore, Alzheimers disease, dementia and Parkinsons disease are pending approval, and approximately five new protocols are added each month.

During the in-office procedure, a mini liposuction is performed on the patient to remove 60 milliliters of fat, which produce approximately 8 million stem cells. The stem cells are isolated and injected back into the patients body at the site of injury or disease. Only local anesthesia is needed, and the patient will go home pain-free.

About Guy DaSilva, MD, ABAARM

Excerpt from:
Sarasota's Dr .Guy DaSilva Introduces Cutting-Edge Stem Cell Therapy For Degenerative Diseases

Posted in Stem Cell Therapy | Comments Off

Vatican Funding for California Stem Cell Agency?

Posted: June 2, 2013 at 3:07 am

So what's with the Vatican sending cash
to the California stem cell agency? One would imagine that is an
improbable event since the agency is involved in human embryonic stem
cell research, which is an anathema to the Roman Catholic church.

However, CIRM President Alan Trounson
earlier this week disclosed the payment in an interview with Patt
Morrison of the Los Angeles Times. He said,

“Last
year I was invited to the Vatican to
present a paper, but when I sent in a summary of what I was going to
say, they decided not to have it. They sent a check to the treasurer
of California and the treasurer rang us up and said, "What the
heck is this check from the Vatican for?" It was for the
inconvenience!”

We wanted to know a little more about
this so we queried the agency about the matter. Kevin McCormack, a
CIRM spokesman, said,

“The money was actually a wire
transfer from the Vatican to us for $453.23 and it went to CIRM's
account. It was to reimburse us for money spent on plane tickets,
etc., for Dr. Trounson to attend the Vatican conference on stem
cells.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/bOQKBXJGmJ8/vatican-funding-for-california-stem.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Bluebird bio of Massachusetts Still Waiting for California Stem Cell Money

Posted: June 2, 2013 at 3:07 am

Seven months after the California stem
cell agency awarded $9.4 million to bluebird bio of Cambridge, Mass.,
the company has yet to receive any of the cash from the Golden State.

Kevin McCormack, a spokesman for the $3
billion agency, this week said negotiations are still underway with
the bluebird, which is planning to go public, but did not elaborate. Post-award negotiations are
common at the agency, but generally take much less time.

The cash from CIRM is scheduled to
assist in clinical trials for a stem cell-gene therapy to correct a genetic disease in young patients with B-thalassemia, a
rare blood disorder that can cause widespread organ damage
and premature death.

Earlier this month, bluebird bio, which
prefers the lower case lettering for its name, announced that it
intends to take the company public in an $86 million offering. In
March, it announced a collaboration with Celgene that provided for an upfront payment of $75 million and promised up to $225 million per
product in potential option fees and clinical and regulatory
milestones. The CIRM grant is conditioned on a matching commitment
from bluebird.

Cash from the stem cell agency can only
be spent on operations within California. According to the CIRM summary of the review of the bluebird application, which was scored
at 73, the company said,

“We will have at least two clinical
sites in California, and more likely up to 4 sites, 2) our viral
vector manufacturing will occur in California, 3) our cell processing
will occur in California, 4) we will hire several consultants and
full-time employees within California to support the program.
Overall, several million dollars will be spent employing the services
of people, academic institutions, and other companies within the
state of California.”

The company has said that it is working
with Donald Kohn at UCLA and Elliot Vichinsky at Oakland's Children's
Hospital.

The bluebird web site lists a
California location for bluebird at 1001 Bayhill Dr, Suite 200, in
San Bruno, which is south of San Francisco. An Internet search
indicates that is a generic address for a number of business
including a realty firm, a roof repair business and a family law
attorney. The California Stem Cell Report has asked bluebird to
clarify the nature of the address.

In an interview last October with Ron Leuty of the
San Francisco Business Times, David Davidson, the lead scientist on
the project, said,

“We began the process (with CIRM)
early in (2012) but discussions have been going on for over a year
about potentially pursuing this.

“The interaction with CIRM has been
extraordinarily collaborative. We had contact with the coordinators
at CIRM that helped us manage the process. It took a lot of effort on
our part to put together a dossier providing support for our program.
It was really like a mini-regulatory filing — on the science, the
preclinical toxicology work that we’ve done, a detailed plan for
the trial, a detailed plan for the budgets, a detailed plan on how we
intended to spend the CIRM money in California. That was an important
part of it. They wanted a clear plan on how this investment would be
spent."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/zR-Ht90u_7o/bluebird-bio-of-massachusetts-still.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Monterey Newspaper Chides California Stem Cell Agency

Posted: June 2, 2013 at 3:07 am

The California stem cell agency and its
former chairman, Robert Klein, came under sharp criticism this week
in an editorial in the Monterey County Herald newspaper.

The editorial cited articles on the
California Stem Cell Report dealing with a $21,630 gift by Klein to
the agency, his employment of the vice chairman of the agency and the
violation of the agency's conflict of interest policies by a grant reviewer.

The editorial was headlined "State Stem Cell Agency Still Up to Old Tricks." The piece said,

“Robert Klein is no longer chairman
of California's stem cell bureaucracy, but it is still doing things
his way. Which is too bad for all concerned.

“Klein is the former developer and
financier who wrote and sponsored the ballot measure that created the
California Institute for Regenerative Medicine. The ballot language
practically guaranteed he would be the chairman, and he ran the
agency the way he ran his businesses, using undisclosed side deals
and other machinations to create webs that outsiders could never
penetrate.

“Now, Klein has been replaced as
chairman, but he is still up to his old tricks.”

The editorial concluded,

“Much has been said about the agency
setting a new more straightforward direction now that Klein is gone,
but so far it seems to be following a twisting and expensive path
toward irrelevance and litigation.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/SGmn7k9T1Vw/monterey-newspaper-chides-california.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Trounson Proposes $70 Million, Fast-Track Stem Cell Clinic Plan for California

Posted: June 2, 2013 at 3:07 am

Alan Trounson, president of the
California stem cell agency, this summer plans to seek $70 million
for creation of what he calls Alpha Clinics, high-powered
organizations that will fast-track stem cell therapies to patients.

The proposal is scheduled to come
before CIRM board at its meeting in late July and would consume a
significant slice of the $700 million to $800 million that the $3
billion agency has left to hand out.

Trounson broached the need for the
clinics as far back as two years ago, but did not put a price tag on
the concept until an interview published online late today in the Los
Angeles Times. The interview will be carried in the print edition of
the paper tomorrow.

In the Q&A session between Times
columnist Patt Morrison and Trounson, he said,

"I'm intending to set up a network of
stem cell clinics in California in the next couple of years, to make
treatments available as clinical trials or as registered treatments
for patients. I'm going to ask the [CIRM] board for about $70 million
to get that set up. It will make California a go-to place for stem
cell therapies. I want to make sure it's part of our medical fabric."

In other media reports in previous
years, Trounson has said the Alpha Clinics would speed delivery of
stem cell-based therapies and reduce costs of clinical trials by
building on the success of specialist cancer, transplant and in-vitro
fertilization clinics.

Leigh Dayton wrote about Trounson's
plan in The Australian last July 14. Dayton said,

“Initially the clinics would use the
capacities and infrastructure in the most advanced university medical
clinics to deliver bone-marrow stem cell therapies. As research
evolves, so will the treatments and services offered.”

Trounson also discussed the Alpha
Clinics during an appearance at USC in 2011. A university publication wrote,

"These clinics will initially serve
to get patients into clinical trials or to offer sound advice to
individuals who might otherwise go overseas to receive harmful stem
cell therapies from disreputable clinics.

"'I’m willing to invest money to
get these [clinics] up,' Trounson said. 'I think if nothing happens
beyond 2017 and we don’t get any refunding, we can leave a
footprint of stem cell clinics in California that will go on
forever.'"

Trounson was not at last week's CIRM
board meeting, but Ellen Feigal, senior vice president for research
and development, said a white paper is being prepared on Alpha
Clinics. She said a concept proposal would be brought to the board
July 25 at a meeting in the San Francisco Bay Area. Once the board
approves the concept, the staff will then prepare and post the RFA.

Interested parties can address
suggestions or questions to Feigal at info@cirm.ca.gov.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/lND8J7NKqzc/trounson-proposes-70-million-fast-track.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off

Page 145«..10 20..144145146 147..150 160..»

Category Archives: Stem Cell Therapy

Mickey’s Before

Sarasota's Dr. Guy DaSilva Introduces Cutting-Edge Stem Cell Therapy For Degenerative Diseases

Cellular Dynamics: California Stem Cell Agency Recipient Plans $57 Million IPO

Pomeroy on Doing the Right Thing and Foster Care

Stem Cell Therapy in Spinal Cord Injury – Video

Sarasota’s Dr .Guy DaSilva Introduces Cutting-Edge Stem Cell Therapy For Degenerative Diseases

Vatican Funding for California Stem Cell Agency?

Bluebird bio of Massachusetts Still Waiting for California Stem Cell Money

Monterey Newspaper Chides California Stem Cell Agency

Trounson Proposes $70 Million, Fast-Track Stem Cell Clinic Plan for California

Categories

Archives

Recommended Sites

Contact Us

Recent Posts